Dustries). For in vitro differentiation, tumor cells were cultured in DMEM

Dustries). For in vitro differentiation, tumor cells were cultured in DMEM/F-12 medium (Life Technologies) containing 10 fetal bovine serum. 293FT and Caco-2 cells were cultured in DMEM (Nissui) containing 10 fetal bovine serum.Subcutaneous XenograftsOne week after lentivirus infection, 16105 cells were injected subcutaneously into 6-week-old NOG mice (Central Institute for Experimental Animals) (n = 3). Tumors were histologically anaCD133 Interacts with PlakoglobinFigure 2. CD133 controls cell-cell adhesion and is required for tumorigenicity of CCC stem cells. (A) CCC stem cells were infected with a lentivirus expressing an shRNA targeting CD133. Cells were subjected to mechanical stress by pipetting in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2. Representative images are shown (upper). The bar graph represents the ratio of cell number/cluster number (lower). Error bars represent the s.d. (n = 3). p = 0.011 with comparison to 50-14-6 site control shRNA by t test. (B) CCC stem cells were treated as described in 18325633 (A). Cell lysates were subjected to immunoblotting with antibodies to the indicated proteins. (C) CCC stem cells were treated as described in (A). Cells were immunostained with antibodies to the indicated proteins (red). TO-PRO-3 iodide was used for nuclear DNA staining (blue). Scale bars represent 20 mm. (D) CCC stem cells were treated as described in (A). Cells were subcutaneously 26001275 transplanted into immunocompromised mice (n = 3). Eleven months after transplantation, mice (upper) and tumors (middle) were photographed. The bar graph represents tumor weight (lower). Error bars represent the s.d. (n = 3). p = 0.007 with comparison to control shRNA by t test. doi:10.1371/journal.pone.0053710.gCD133 Interacts with Plakoglobinlyzed after hematoxylin and eosin (HE) staining. This study was approved by Animal Ethics Committee, The University of Tokyo, Tokyo, Japan. All animal experimental protocols were performed in accordance with the politics of the Animal Ethics Committee, The University of Tokyo, Tokyo, Japan.Quantitative RT-PCRTotal RNA was extracted using NucleoSpin RNA Clean-up kit (Takara) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara). Real-time PCR was performed using LightCycler480 SYBR Green I Master and a LightCycler480 Instrument (Roche). Results were normalized with the detected value for Tubastatin A glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers used in realtime PCR were as follows: GAPDH forward (59-GCACCGTCAAGGCTGAGAAC-39), GAPDH reverse (59-TGGTGAAGACGCCAGTGGA-39); CD133 forward (59-AGTGGCATCGTGCAAACCTG-39), CD133 reverse (59CTCCGAATCCATTCGACGATAGTA-39); SOX2 forward (59TTGCTGCCTCTTTAAGACTAGGA-39), SOX2 reverse (59CTGGGGCTCAAACTTCTCTC-39); Lgr5 forward (59GATTTCCTGCTTGACTTTGAGG-39), Lgr5 reverse (59GCAGGTGTTCACAGGGTTTG-39); plakoglobin forward (59GATCTTCCGGCTCAACACC-39), plakoglobin reverse (59GATGTTCTCCACCGACGAGT-39); desmoglein-2 forward (59GGAAATTTTCAAGCTTTTGATGA-39), desmoglein-2 reverse (59-CCACAGAGATCCAATTATCTCTATCTT-39).human protein database (32,968 protein sequences as of Sep 12, 2011) using Mascot ver. 2.3.02 (Matrix Science). Methionine oxidation, protein N-terminal acetylation and pyro-glutamination for N-terminal glutamine were set as variable modifications. A maximum of two missed cleavages was allowed in our database search and the tolerance for mass deviation was set to 3 parts per million (ppm) for peptide masses and 0.8 Da for MS/MS peaks, respectively. Protein identification was base.Dustries). For in vitro differentiation, tumor cells were cultured in DMEM/F-12 medium (Life Technologies) containing 10 fetal bovine serum. 293FT and Caco-2 cells were cultured in DMEM (Nissui) containing 10 fetal bovine serum.Subcutaneous XenograftsOne week after lentivirus infection, 16105 cells were injected subcutaneously into 6-week-old NOG mice (Central Institute for Experimental Animals) (n = 3). Tumors were histologically anaCD133 Interacts with PlakoglobinFigure 2. CD133 controls cell-cell adhesion and is required for tumorigenicity of CCC stem cells. (A) CCC stem cells were infected with a lentivirus expressing an shRNA targeting CD133. Cells were subjected to mechanical stress by pipetting in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2. Representative images are shown (upper). The bar graph represents the ratio of cell number/cluster number (lower). Error bars represent the s.d. (n = 3). p = 0.011 with comparison to control shRNA by t test. (B) CCC stem cells were treated as described in 18325633 (A). Cell lysates were subjected to immunoblotting with antibodies to the indicated proteins. (C) CCC stem cells were treated as described in (A). Cells were immunostained with antibodies to the indicated proteins (red). TO-PRO-3 iodide was used for nuclear DNA staining (blue). Scale bars represent 20 mm. (D) CCC stem cells were treated as described in (A). Cells were subcutaneously 26001275 transplanted into immunocompromised mice (n = 3). Eleven months after transplantation, mice (upper) and tumors (middle) were photographed. The bar graph represents tumor weight (lower). Error bars represent the s.d. (n = 3). p = 0.007 with comparison to control shRNA by t test. doi:10.1371/journal.pone.0053710.gCD133 Interacts with Plakoglobinlyzed after hematoxylin and eosin (HE) staining. This study was approved by Animal Ethics Committee, The University of Tokyo, Tokyo, Japan. All animal experimental protocols were performed in accordance with the politics of the Animal Ethics Committee, The University of Tokyo, Tokyo, Japan.Quantitative RT-PCRTotal RNA was extracted using NucleoSpin RNA Clean-up kit (Takara) and reverse-transcribed into cDNA using PrimeScript RT Master Mix (Takara). Real-time PCR was performed using LightCycler480 SYBR Green I Master and a LightCycler480 Instrument (Roche). Results were normalized with the detected value for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Primers used in realtime PCR were as follows: GAPDH forward (59-GCACCGTCAAGGCTGAGAAC-39), GAPDH reverse (59-TGGTGAAGACGCCAGTGGA-39); CD133 forward (59-AGTGGCATCGTGCAAACCTG-39), CD133 reverse (59CTCCGAATCCATTCGACGATAGTA-39); SOX2 forward (59TTGCTGCCTCTTTAAGACTAGGA-39), SOX2 reverse (59CTGGGGCTCAAACTTCTCTC-39); Lgr5 forward (59GATTTCCTGCTTGACTTTGAGG-39), Lgr5 reverse (59GCAGGTGTTCACAGGGTTTG-39); plakoglobin forward (59GATCTTCCGGCTCAACACC-39), plakoglobin reverse (59GATGTTCTCCACCGACGAGT-39); desmoglein-2 forward (59GGAAATTTTCAAGCTTTTGATGA-39), desmoglein-2 reverse (59-CCACAGAGATCCAATTATCTCTATCTT-39).human protein database (32,968 protein sequences as of Sep 12, 2011) using Mascot ver. 2.3.02 (Matrix Science). Methionine oxidation, protein N-terminal acetylation and pyro-glutamination for N-terminal glutamine were set as variable modifications. A maximum of two missed cleavages was allowed in our database search and the tolerance for mass deviation was set to 3 parts per million (ppm) for peptide masses and 0.8 Da for MS/MS peaks, respectively. Protein identification was base.